BioReference Labs’ GenPath to Participate in NCI-Match

BioReference Labs signed a collaboration agreement with the National Cancer Institute and ECOG-ACRIN Cancer Research Group in the Institute’s Molecular Analysis for Therapy Choice (NCI-MATCH) trial.  The purpose of the NCI-MATCH trial is to determine the efficacy of certain cancer therapeutics that target a patient’s genetic alterations, regardless of the cancer type.

Source: https://www.genomeweb.com/clinical-lab-management/bioreference-labs-genpath-participate-nci-match